Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q2 FY24 results · Jul–Sep 2023
Astec LifeSciences reported revenue from operations of ₹110.79 crore (down 44.5% from Q2 FY23) and net loss of ₹13.42 crore for Q2 FY24 (Jul–Sep 2023), on a consolidated basis.
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 110.79 | 199.75 | −44.5% | 142.85 | −22.4% |
| Other income | 0.98 | 3.99 | −75.4% | 1.71 | −42.7% |
| Total income | 111.77 | 203.73 | −45.1% | 144.56 | −22.7% |
| Profit before tax | (17.60) | 24.58 | Turned loss | (11.01) | Loss widened |
| Net profit for the period | (13.42) | 18.31 | Turned loss | (8.19) | Loss widened |
| Attributable to shareholders of the company | (13.43) | 18.31 | Turned loss | (8.19) | Loss widened |
| EPS, basic (₹) | (6.85) | 9.34 | Turned loss | (4.18) | Loss widened |
| Net margin (%) | -12.1 | 9.2 | -5.7 |
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 110.79 | 199.75 | −44.5% | 142.85 | −22.4% |
| Other income | 0.96 | 3.98 | −76.0% | 1.70 | −43.7% |
| Total income | 111.74 | 203.73 | −45.2% | 144.55 | −22.7% |
| Profit before tax | (17.64) | 24.56 | Turned loss | (11.03) | Loss widened |
| Net profit for the period | (13.45) | 18.30 | Turned loss | (8.21) | Loss widened |
| EPS, basic (₹) | (6.86) | 9.34 | Turned loss | (4.19) | Loss widened |
| Net margin (%) | -12.1 | 9.2 | -5.7 |
Consolidated
- Filed with BSE
- 30 Oct 2023, 15:13 IST
- Board meeting
- 27 Oct 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Oct 2023, 15:13 IST
- Board meeting
- 27 Oct 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE